Skip to Main Content

P7977-1231 - FissionA Phase 3, Multicenter, Randomized, Active-Controlled, Study to Investigate Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in Treatment-Naïve Patients with Chro

Principal Investigator

Eugene Schiff

Clinical Trial ID

Institutional Protocol # 20111165

Clinical Trial Summary


Phase

Phase III


Funding Agency/Sponsor

Intramural


Disease



Contact Information

Study Contact Marlene McGregory
Phone Number 305-243-2647